Syndax Pharmaceuticals
Open
$21.29
Prev. Close
$21.29
High
$21.30
Low
$21.29
Market Snapshot
$1.79B
-6.3
-3.72
$23.68M
298
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
emptyResult
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Recently from Cashu
Syndax Pharmaceuticals Reports Strong Q4 Earnings and Promising Market Outlook
Syndax Pharmaceuticals Reports Strong Q4 Earnings, Demonstrating Market Commitment Syndax Pharmaceuticals (NASDAQ: SNDX) releases its Q4 earnings results, showcasing remarkable recovery and strong gro…
Syndax Pharmaceuticals Reports Strong Q4 Earnings and Promising Future Growth Outlook
Syndax Pharmaceuticals Reports Strong Q4 Earnings and Optimism for Future Growth Syndax Pharmaceuticals continues to demonstrate robust growth in the biopharmaceutical sector, as evidenced by its four…
Syndax Pharmaceuticals Q4 Earnings Show Promising Growth and Optimism for Future Innovations
Syndax Pharmaceuticals: Strong Q4 Performance Signals Growth Potential in Biotech Sector Syndax Pharmaceuticals recently reports its Q4 earnings, showcasing notable progress that enhances its standing…
Syndax Pharmaceuticals Advances Oncology Pipeline Amid Market Challenges and Competition
Syndax Pharmaceuticals Advances Oncology Pipeline Amid Challenging Market Conditions Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, continues to make significant strides in its on…